Nebivolol Torrent Pharma (Uk)

Nebivolol, the active ingredient in Nebivolol Torrent Pharma, is a beta‑1 selective adrenergic receptor blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and chronic heart failure in adult patients.

GNH USA supplies Nebivolol Torrent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory compliance across EU and other markets.

Nebivolol acts on the cardiovascular system to lower blood pressure and improve cardiac performance in specific disease states.

Hypertension: reduces systolic and diastolic blood pressure in essential hypertension. Heart failure: improves left ventricular ejection fraction and reduces symptoms in chronic heart failure. Cardiovascular risk management: assists in blood‑pressure control to lower overall cardiovascular risk in patients with hypertension.

Nebivolol may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate headache. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general tiredness or reduced energy. - Bradycardia: slower than normal heart rate. - Nasal congestion: stuffy nose.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical attention. - Acute bronchospasm: especially in patients with asthma or COPD. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating nebivolol therapy, clinicians should evaluate several safety considerations. - Blood pressure monitoring: check baseline and periodic readings to avoid hypotension. - Cardiac function assessment: evaluate heart rate and conduction system, especially in patients with bradycardia. - Respiratory caution: use carefully in asthma or chronic obstructive pulmonary disease. - Concomitant beta‑blockers: avoid combining with other β‑blockers unless clinically justified. - Renal impairment: dose may need adjustment in severe renal dysfunction. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other β‑blockers: additive bradycardia and AV‑block risk. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): may cause excessive heart‑rate slowing. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect, requiring blood‑pressure monitoring. - ACE inhibitors or ARBs: combined use can lead to additive blood‑pressure reduction.